Shared Immune-Inflammatory Gene Pathways and Drug Targets in PCOS and T2DM

Overview

This study identified nine common immune-inflammatory hub genes linking polycystic ovary syndrome (PCOS) and type 2 diabetes mellitus (T2DM). Bioinformatics and experimental validation revealed key pathways and predicted potential therapeutic drugs targeting these genes.

Background

PCOS is a prevalent endocrine disorder in reproductive-aged women, often complicated by insulin resistance and increased risk of T2DM. Conversely, T2DM patients of reproductive age have a higher prevalence of PCOS, indicating a bidirectional comorbidity. Both conditions share metabolic dysfunctions, including insulin resistance and hyperandrogenism, but the underlying genetic and molecular mechanisms remain incompletely understood. Identifying shared gene pathways may improve understanding and treatment strategies.

Data Highlights

Key Findings

• 239 common differentially expressed genes (DEGs) were found between PCOS and T2DM, mainly related to immune regulation and inflammation.
• Nine hub genes (ITGAM, ITGB2, SPI1, C1QB, CCR5, C3AR1, LY86, AIF1, IRF8) were identified and validated by RT-qPCR.
• These hub genes are involved in neutrophil degranulation, dendritic cell chemotaxis, follicular B cell differentiation, synapse pruning, and integrin complex regulation.
• Gene pathways linked to infections such as Staphylococcus aureus and pertussis were enriched, suggesting immune dysregulation.
• Regulatory networks involving 19 transcription factors and 170 miRNAs were constructed, highlighting complex gene regulation.
• Forty potential drugs targeting hub genes were predicted, including maraviroc, cenicriviroc, PF-04634817 (CCR5 targets), butein (ITGB2), dimethyl sulfoxide (ITGAM), and rovelizumab (ITGB2 and ITGAM).

Clinical Implications

The identification of shared immune-inflammatory hub genes provides insight into the molecular link between PCOS and T2DM, emphasizing the role of immune dysregulation in their comorbidity. Targeting these hub genes with predicted drugs, such as CCR5 antagonists and integrin inhibitors, may offer novel therapeutic avenues. However, clinical validation is necessary before these treatments can be recommended.

Conclusion

This study elucidates common immune-inflammatory genetic pathways underlying PCOS and T2DM and proposes potential drug repurposing strategies. These findings enhance understanding of their shared pathogenesis and may guide future therapeutic development.

Related Resources & Content

1. Identification of Common Immune-Inflammatory Gene Pathways and Drug Repurposing in PCOS and T2DM, 2024